BC Innovations | Feb 19, 2015
Product R&D

Banking on stem cells

While stem cell developers wrestle with fine-tuning cell types, improving protocols and calling for better regulatory guidelines, few in the field are addressing one of the looming problems likely to hit once more products reach...
BioCentury | Oct 29, 2012
Emerging Company Profile

Regenesance: Stopping the MAC attack

Regenesance B.V. is developing mAbs against complement 6 that may halt nerve damage and provide a better safety profile than standard of care for the orphan neurological disease myasthenia gravis. The mAbs are in lead...
BC Week In Review | Dec 5, 1994
Company News

Telios news

TLIO cut an additional 42 positions, leaving the company with 35 employees, primarily in the areas of R&D and general and administrative functions. TLIO, which had pared its staff from 138 to 80 in November,...
Items per page:
1 - 3 of 3